Immune Profiling of COVID19-patients Admitted to ICU

COVID-19 Clinical Trial

— IMPROVISE  

Official title:

Immune Profiling of COVID-19-infected Patients Admitted to the Intensive Care Unit (ICU): the IMPROVISE Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04473131
• Other study ID #: MRC-05-007
• Status: Recruiting
• Start date: April 27, 2020
• Est. completion date: June 2022

Study information

• Verified date: July 2020
• Source: Hamad Medical Corporation
• Contact: Dr. Ali Ait Hssain
• Phone: 77172526
• Email: a_aithssain[@]hotmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

SARS-CoV-2 is the novel coronavirus responsible for COVID-19, coronavirus disease 2019. This new coronavirus was first detected in Wuhan, China in late December 2019. According to WHO, the incidence rate of COVID-19 is prominent among adults and elderly people, reaching so far >2 million cases globally. Meanwhile, confirmed death cases reached >126 thousands of reported cases in 185 countries and still increasing. We anticipate that immunological differences among COVID19-infected patients might be a reason behind the variation of patient outcomes. Therefore, we intend to investigate cellular and humoral immune responses of COVID19-positive patients, and we claim to discover new indicators of patients' prognosis. Our target population includes three categories of patients staying at ICU, HMC (COVID19-positive vs. COVID19-negative vs. healthy control). Throughout their ICU stay, multiple blood samples will be screened for leukocytes surface markers, leukocytes' production of certain molecules, and circulating cytokines/chemokines/checkpoint inhibitors. Their plasma/serum will be used as well for immune proteomics, metabolomics, and other serological tests. Such parameters can provide the more comprehensive status of COVID19-infected patients at infection onset, during treatment intake, and at recovery or relapse stage. Following analysis, the main prospective outcome of this study is to identify the most reflective markers of COVID19-positive patients' outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: June 2022
• Est. primary completion date: June 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Admitted to ICU for suspicious COVID-19

• Signed consent form

Exclusion Criteria:

• Immuno-compromised or immuno-deficient patients

• Diagnosed with any immunological disorders, cancer, and onco-hematological diseases at the inclusion date

• Patients under treatment or treated within 5 years before inclusion or at the end of chemotherapy within the 6 months prior to inclusion date

• Patients under any immune-suppressive medications, antibody therapy, corticosteroids, bone marrow transplant under the last 6 months of inclusion

• Unsigned consent form

Related Conditions & MeSH terms

• COVID-19

Intervention

Other:
• No intervention
Only blood samples will be taken from participants for this study

Locations

Country	Name	City	State
Qatar	Hamad Medical Corporation	Doha

Sponsors (3)

Lead Sponsor	Collaborator
Hamad Medical Corporation	Qatar University, Weill Cornell Medical College in Qatar

Country where clinical trial is conducted

Qatar, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To create an immune profile for each COVID19-positive patient during their ICU stay	A descriptive analysis of the innate and adaptive immune cells (phenotypically and functionally), along with circulating pro- and anti-inflammatory cytokines, and the dynamic change of immune cells and cytokines throughout the first 4 weeks of the COVID-19 infection.	8 to 12 months
Primary	To correlate patients' immune profile to disease severity and patient's outcome	A correlative analysis of the immune cells and cytokines levels with the COVID-19 severity and with the patient's outcome following their stay at the ICU. An attempt to identify markers associated with the disease severity and predictive measures to the patient's outcome.	4 to 6 months